
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : DAAN Biotherapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
DAAN and GC Cell Sign Deal for Antibody Tech to Boost CAR-T And CAR-NK
Details : Under the licensing agreement, GC Cell holds the exclusive rights to utilize DAAN Biotherapeutics' antibody sequence in the research and development of CAR-T and CAR-NK therapies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 21, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : DAAN Biotherapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AB-205,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
GC Cell Doses First Patient in Phase 1 GCC2005 CD5 CAR-NK Therapy Trial
Details : GCC2005 (AB‑205) is a novel CD5 CAR‑NK cell therapy candidate, which is currently being evaluated for the treatment of T‑cell lymphoma.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 12, 2025
Lead Product(s) : AB-205,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : GCC2005
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Artiva Biotherapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GCC2005 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, T-Cell.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 21, 2024
Lead Product(s) : GCC2005
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Artiva Biotherapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable

GC Cell and PT Bifarma Sign Licensing Deal For Immuncell-LC in Indonesia
Details : Bifarma will be granted the exclusive rights to develop, manufacture, and commercialize Immuncell-LC, an anti-cancer immune cell therapy, for 15 years.
Product Name : Immuncell-LC
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 10, 2024

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201
Details : AB-201 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 02, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AB-201,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
GC Cell's AB-201 Cancer Treatment To Begin Phase 1 Trials with Lunit AI
Details : AB-201 is a novel CAR-NK cell therapy targeting solid tumors, evaluated in Phase 1/2 studies for HER2-overexpressing breast cancer, representing a breakthrough in cancer immunotherapy.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 08, 2024
Lead Product(s) : AB-201,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CT303
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis
Details : CT303 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 28, 2022
Lead Product(s) : CT303
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CT303
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With ARDS
Details : CT303 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Respiratory Distress Syndrome.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 14, 2022
Lead Product(s) : CT303
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Immuncell-LC
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Rivaara Labs
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Rivaara Immune has obtained the exclusive right to develop and commercialize Immuncell-LC® within India for liver cancer.
Product Name : Immuncell-LC
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 03, 2022
Lead Product(s) : Immuncell-LC
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Rivaara Labs
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
Details : Immuncell-Lc is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Pancreatic Ductal.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 21, 2021
